Raymond James & Associates Cytokinetics Inc Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
A detailed history of Raymond James & Associates transactions in Cytokinetics Inc stock. As of the latest transaction made, Raymond James & Associates holds 3,873 shares of CYTK stock, worth $216,616. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,873
Previous 7,904
51.0%
Holding current value
$216,616
Previous $554,000
62.27%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CYTK
# of Institutions
406Shares Held
126MCall Options Held
3.29MPut Options Held
2.01M-
Black Rock Inc. New York, NY14.7MShares$821 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$640 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.14MShares$455 Million0.28% of portfolio
-
Wellington Management Group LLP Boston, MA7.51MShares$420 Million0.07% of portfolio
-
State Street Corp Boston, MA6.55MShares$366 Million0.02% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.27B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...